Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae

Antimicrob Agents Chemother. 2003 Sep;47(9):2765-9. doi: 10.1128/AAC.47.9.2765-2769.2003.

Abstract

Community distribution of azithromycin has an important role to play in trachoma control. Previous studies have suggested that this may increase the prevalence of macrolide-resistant Streptococcus pneumoniae. S. pneumoniae was isolated from children under 7 years of age in Rombo District, northern Tanzania, before and 2 and 6 months after community-wide administration of azithromycin. Overall carriage rates were 11, 12, and 7%, respectively. Only one macrolide-resistant isolate carrying the mef gene was obtained 6 months after azithromycin administration. This contrasted with cotrimoxazole and penicillin resistance, both of which were common (cotrimoxazole resistance, 42, 43, and 47%, and penicillin resistance, 21, 17, and 16% at baseline, 2 months, and 6 months, respectively). There was a significant association between cotrimoxazole and penicillin resistance (P < 0.0001, Fisher's exact). These data suggest that in communities where macrolide resistance is rare, azithromycin distribution for trachoma control is unlikely to increase the prevalence of resistant organisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / administration & dosage
  • Azithromycin / therapeutic use*
  • Carrier State / drug therapy*
  • Carrier State / microbiology*
  • Child
  • Child, Preschool
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / microbiology
  • Drug Resistance, Bacterial
  • Humans
  • Infant
  • Microbial Sensitivity Tests
  • Penicillin Resistance
  • Pneumococcal Infections / drug therapy*
  • Pneumococcal Infections / microbiology*
  • Population Surveillance
  • Streptococcus pneumoniae / drug effects*
  • Trachoma / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Azithromycin